Scholar Rock Reports Q3 2026 Third Quarter Results Exceeding Estimates
Scholar Rock Holding Corporation (SRRK) reported third-quarter financial results that surpassed analyst expectations for both earnings and revenue. The company posted a GAAP EPS of -$0.81, beating estimates by $0.05, while revenue reached $0.57 million, exceeding projections by $0.29 million. As of September 30, 2026, the company maintained a strong liquidity position with $413.6 million in cash, cash equivalents, and marketable securities. The results come amid significant clinical focus on ISEMBYLD for Spinal Muscular Atrophy (SMA) treatment and recent positive analyst sentiment, including being added to Wedbush's 'Best Ideas List.'
Tickers: $SRRK
Topics: cash position earnings beat financial results revenue beat
Read the full article at Seeking Alpha
Part of the story Scholar Rock Reports Q3 2026 Results Following ISEMBYLD FDA Approval (5 articles)